Temozolomide Capsule
Product Images NDC 16571-820

13 FDA label images from Rising Pharma Holdings, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Temozolomide (NDC 16571-820). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Temozolomide-table1 (Temozolomide Table1)

Temozolomide-table1 (Temozolomide Table1)
A data table titled 'Dosage Modifications Due to Adverse Reactions During Concomitant Use Phase' for temozolomide. It lists adverse reactions (Absolute Neutrophil Count, Platelet Count, Non-hematological Adverse Reaction) alongside recommended actions for interruption and discontinuation of temozolomide capsules based on lab values and severity grades.*
FDA Label Image

Temozolomide-table2 (Temozolomide Table2)

Temozolomide-table2 (Temozolomide Table2)
A table titled 'Dosage Modifications Due to Adverse Reactions During Maintenance and Adjuvant Treatment' for temozolomide. It outlines adverse reactions related to Absolute Neutrophil Count, Platelet Count, and Nonhematological Adverse Reactions (excluding alopecia, nausea, vomiting), with instructions on interruption, dose reduction, and discontinuation criteria for temozolomide capsules.*
FDA Label Image

Temozolomide-table3 (Temozolomide Table3)

Temozolomide-table3 (Temozolomide Table3)
Table presenting adverse reactions occurring in 10% or more of patients with newly diagnosed glioblastoma during different treatment phases: concomitant use with radiation therapy and temozolomide (N=288), radiation therapy alone (N=285), and maintenance use of temozolomide (N=224). Reactions are categorized by system (skin, general, gastrointestinal, nervous) with percentages for all grades and grade 3 or higher severity.*
FDA Label Image

Temozolomide-table4 (Temozolomide Table4)

Temozolomide-table4 (Temozolomide Table4)
Data table listing adverse reactions occurring in 10% or more of patients with refractory anaplastic astrocytoma treated with temozolomide (N=158). The table categorizes adverse reactions by system (gastrointestinal, general, nervous system, cardiovascular, resistance mechanism) and shows the percentage of all reactions and Grades 3-4 severity.*
FDA Label Image

Temozolomide-table5 (Temozolomide Table5)

Temozolomide-table5 (Temozolomide Table5)
A data table titled 'Grade 3 to 4 Hematologic Laboratory Abnormalities That Worsened from Baseline in Patients with Refractory Anaplastic Astrocytoma' showing percentages of specific hematologic abnormalities in patients treated with temozolomide. The abnormalities listed include decreased lymphocytes (55%), decreased platelets (19%), decreased neutrophils (14%), decreased leukocytes (11%), and decreased hemoglobin (4%).*
FDA Label Image

Temozolomide-structural-formula (Temozolomide Structural Formula)

Temozolomide-structural-formula (Temozolomide Structural Formula)
Chemical structure of temozolomide showing its molecular framework with labeled nitrogen, oxygen, and methyl groups as part of the heterocyclic compound.*
FDA Label Image

Temozolomide-figure-01 (Temozolomide Figure 01)

Temozolomide-figure-01 (Temozolomide Figure 01)
A Kaplan-Meier survival curve chart titled 'ITT Population: Overall Survival' showing probability of survival over time from randomization in months. Two curves represent treatment groups: 'RT + TMZ' (radiotherapy plus temozolomide) with a higher survival probability over time and 'RT Only' with lower survival. Median survival times are marked approximately at 12.1 months for RT Only and 14.6 months for RT + TMZ. A hazard ratio (HR) of 0.63 with 95% confidence interval (0.52-0.75) and a log-rank P-value <0.0001 are displayed, indicating statistical comparison of survival between groups.*
FDA Label Image

Temozolomide-5mg (Temozolomide 5mg)

Temozolomide-5mg (Temozolomide 5mg)
Label for Temozolomide Capsules, USP 5 mg by Rising Pharma Holdings, Inc. The label indicates the capsules are for oral administration and cytotoxic with special handling. It includes packaging instructions such as storage at 25°C (77°F) and dispensing in light-resistant containers. The package contains 5 capsules. The label also notes the product is manufactured in India and is Rx only.*
FDA Label Image

Temozolomide-20mg (Temozolomide 20mg)

Temozolomide-20mg (Temozolomide 20mg)
Packaging label for Temozolomide Capsules, USP 20 mg, an oral capsule form by Rising Pharma Holdings, Inc. The label displays the product name, strength, route of administration, and a warning highlighting that the drug is cytotoxic and requires special handling. The package contains 5 capsules. Additional information includes storage instructions and manufacturer details.*
FDA Label Image

Temozolomide-100mg (Temozolomide 100mg)

Temozolomide-100mg (Temozolomide 100mg)
The label for Temozolomide Capsules USP 100 mg by Rising Pharma Holdings, Inc. The label indicates oral administration, a package size of 5 capsules, and highlights special handling caution for the cytotoxic agent. The label includes storage instructions and manufacturer details, including code and issue date.*
FDA Label Image

Temozolomide-140mg (Temozolomide 140mg)

Temozolomide-140mg (Temozolomide 140mg)
Label for Temozolomide Capsules, USP 140 mg oral capsules by Rising Pharma Holdings, Inc. The packaging contains 5 capsules. The label highlights the cytotoxic nature of the drug with a special handling warning and instructs to store at controlled room temperature. Manufactured in India, the label includes a barcode and regulatory details.*
FDA Label Image

Temozolomide-180mg (Temozolomide 180mg)

Temozolomide-180mg (Temozolomide 180mg)
Temozolomide Capsules, USP 180 mg oral capsules in a 5-capsule package from Rising Pharma Holdings, Inc. The label highlights the cytotoxic nature with a special handling caution and specifies storage instructions. Manufactured in India for Rising Pharma Holdings, Inc., East Brunswick, NJ.*
FDA Label Image

Temozolomide-250mg (Temozolomide 250mg)

Temozolomide-250mg (Temozolomide 250mg)
Temozolomide Capsules USP 250 mg for oral administration, packaged in a container of 5 capsules. The label specifies that the product is cytotoxic and requires special handling. Manufactured for Rising Pharma Holdings, Inc., with storage instructions and barcode visible on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.